Coronavirus

Resonate Data Shows Consumer Economic and Health Concerns are Stabilizing

After years of rising anxiety, Americans are ready for a pause RESTON, Va., June 18, 2024 /PRNewswire/ -- Resonate, a pioneer…

5 months ago

Emergex Announces MHRA Approval of MIA (IMP) Manufacturing and Import Authorisation License

ABINGDON, United Kingdom, June 18, 2024 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical-stage biotechnology company…

5 months ago

Replimune Announces $100 Million Private Placement Financing

- Led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional investors…

5 months ago

Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More SHELTON, CT…

5 months ago

Hospital PMI® at 58.4%; May 2024 Hospital ISM® Report On Business®

TEMPE, Ariz., June 7, 2024 /PRNewswire/ -- Economic activity in the hospital subsector grew in May for the ninth consecutive month after…

6 months ago

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

Manufacturing is underway and doses of Moderna's Spikevax 2024-2025 formula will be ready to ship as early as August, pending…

6 months ago

ISM® Welcomes Steve Miller as Esteemed Chair of ISM Services Business Survey Committee

Anthony S. Nieves announces transition after distinguished leadership in chair role for over a decade TEMPE, Ariz., June 6, 2024…

6 months ago

Services PMI® at 53.8%; May 2024 Services ISM® Report On Business®

Business Activity Index at 61.2%; New Orders Index at 54.1%; Employment Index at 47.1%; Supplier Deliveries Index at 52.7% TEMPE,…

6 months ago

Theralase(R) Technology Effective in Virus Inactivation

TORONTO, ON / ACCESSWIRE / June 4, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

6 months ago

The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More SHELTON, CT…

6 months ago